Results of a Multicentre Survey Evaluating Clinical Practice of Port and Broviac Management in Paediatric Oncology

Simón, A.; Graf, Norbert; Furtwängler, Rhoikos

doi:10.1055/s-0033-1333762

Cited by 23 publications

(42 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The practice of CVAD care and other strategies to prevent HAIs in paediatric cancer patients differ markedly between the PCCs participating in this study [34]. A survey performed in 2012 including 29 PCCs from Germany, Austria and Switzerland [53] has confirmed this finding. According to single-centre studies, the routine use of a taurolidine-containing antimicrobial lock solution prevents BSIs in paediatric cancer patients [20,28,48].…”

Section: Discussionsupporting

confidence: 60%

Bloodstream infection in paediatric cancer centres—leukaemia and relapsed malignancies are independent risk factors

Ammann

Schrey

et al. 2015

Eur J Pediatr

Self Cite

View full text Add to dashboard Cite

• Paediatric cancer patients face an increased risk of nosocomial bloodstream infections (BSIs). • In most cases, these BSIs are associated with the use of a long-term central venous catheter (Broviac, Port), severe and prolonged immunosuppression (e.g. neutropenia) and other chemotherapy-induced alterations of host defence mechanisms (e.g. mucositis). What is New: • This study is the first multicentre study confirming relapsed malignancy as an independent risk factor for BSIs in paediatric cancer patients. • It describes the epidemiology of nosocomial BSI in paediatric cancer patients mainly outside the stem cell transplantation setting during conventional intensive therapy and argues for prospective surveillance programmes to target and evaluate preventive bundle interventions.

show abstract

Section: Discussionsupporting

confidence: 60%

Bloodstream infection in paediatric cancer centres—leukaemia and relapsed malignancies are independent risk factors

Ammann

Schrey

et al. 2015

Eur J Pediatr

Self Cite

View full text Add to dashboard Cite

show abstract

“…Central line bundles were reported to prevent CLABSI, especially in intensive care units (7)(8)(9)(10)(11). Studies including CLB applications for long-term TIVADs in paediatric cancer patients have mainly focused on the impact on CLABSI rates in clinical settings, and to our knowledge, no available data are available in paediatric cancer patients (12)(13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

Central line bundle including split-septum device and single-use prefilled flushing syringes to prevent port-associated bloodstream infections: A cost and resource-utilization analysis

Devrim

Ozkul

Çağlar

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Central line bundle programs were found to be effective in decreasing central line-associated bloodstream infection rates in pediatric cancer patients with ports. However, cost-effectiveness studies of central line bundle programs in pediatric cancer patients are limited, and most available data are from intensive care unit or adult studies.Methods: In this cross-sectional study spanning 6 years, comprehensive assessment of total health care costs attributable to CLABSI's associated with ports between two periods.Results: This cross-sectional study was carried out in the pediatric hematology-oncology ward of Dr. Behçet Uz Children's Hospital from 1 August November 2011 to 31 July 2017. The CLABSI rates decreased significantly from 8.31 CLABSIs to 3.04 per 1000 central line days (p<0.001). In the pre-bundle period, total attributable costs spent for of patients with CLABSI were $130661, and in the bundle period, total attributable costs spent for patients with CLABSI were $116579. Within bundle implantation, 71 potential CLABSI were prevented, which saved an additional $208977. Conclusion: Our study shows that central line bundles decreases not only the CLABSI rate but also decreases attributable costs due to CLABSI. Expenses spent for bundle elements, were covered by savings by preventing CLABSI with higher costs

show abstract

“…Bei kinderonkologischen Patienten wird meist schon zu Beginn der zytostatischen Behandlung [39] ein dauerhafter zentraler Gefäßkatheter (central versus access device; CVAD) implantiert [84,87] entweder als getunnelter Broviac-/Hickman-Katheter oder voll implantierter Port-Katheter. Diese CVADs sind ein unverzichtbarer Bestandteil des gesamten Behandlungskonzepts.…”

Section: Introductionunclassified

Kinderonkologie: Erhaltungspflege von Broviac- und Port-Kathetern

Scheler¹,

Simon²

2017

Krankenh.hyg. up2date

View full text Add to dashboard Cite

Results of a Multicentre Survey Evaluating Clinical Practice of Port and Broviac Management in Paediatric Oncology

Cited by 23 publications

References 17 publications

Bloodstream infection in paediatric cancer centres—leukaemia and relapsed malignancies are independent risk factors

Bloodstream infection in paediatric cancer centres—leukaemia and relapsed malignancies are independent risk factors

Central line bundle including split-septum device and single-use prefilled flushing syringes to prevent port-associated bloodstream infections: A cost and resource-utilization analysis

Kinderonkologie: Erhaltungspflege von Broviac- und Port-Kathetern

Contact Info

Product

Resources

About